Valuation: NovoCure Limited

Market Cap 2.01B 1.76B 1.62B 1.5B 2.85B 191B 2.89B 19.37B 7.54B 93.93B 7.53B 7.37B 326B P/E 2026 *
-10.9x
P/E 2027 * -14.5x
Enterprise Value 1.78B 1.56B 1.44B 1.34B 2.54B 170B 2.57B 17.23B 6.7B 83.53B 6.7B 6.55B 290B EV / Sales 2026 *
2.53x
EV / Sales 2027 * 2.59x
Free-Float
89.99%
Yield 2026 *
-
Yield 2027 * -
1 day-1.50%
1 week+11.95%
Current month+11.95%
1 month+0.65%
3 months+63.86%
6 months+17.70%
Current year+31.17%
1 week 15.29
Extreme 15.29
17.8
1 month 13.43
Extreme 13.43
18.35
Current year 9.82
Extreme 9.82
18.92
1 year 9.82
Extreme 9.82
18.92
3 years 9.82
Extreme 9.82
42.69
5 years 9.82
Extreme 9.82
195.78
10 years 5.95
Extreme 5.95
232.76
Manager TitleAgeSince
Chief Executive Officer 46 01/12/2025
Director of Finance/CFO 52 01/01/2025
Chief Tech/Sci/R&D Officer - 17/01/2023
Director TitleAgeSince
Chairman 63 01/01/2009
Director/Board Member 64 05/08/2011
Director/Board Member 68 31/05/2018
Date Insider Type Main position Quantity % Market Cap.
06-30Free

Chief Executive Officer

1,905 0.0016%
06-30Free

General Counsel

1,299 0.0011%
06-30Free

Head of Human Resources

1,905 0.0016%
Change 5-day change 1-year change 3-year change Capi.($)
-1.01%+11.95%+0.41%-58.71% 2.01B
+0.48%+1.11%+28.54%-2.48% 12.52B
-0.86%-2.63%+63.97%+35.90% 6.1B
+0.24%+4.09%+8.53%+14.94% 5.81B
-0.95%+0.90% - - 4.29B
-0.09%+1.76%-33.27%+9.48% 4.04B
-0.56%+0.95%-25.83%-23.58% 3.89B
-1.86%+3.26%+26.85%+262.96% 1.89B
-0.50%-0.60%+56.01%-6.83% 1.53B
+0.49%+4.53%-13.14%-45.23% 1.31B
Average -0.54%+4.22%+12.45%+20.72% 4.34B
Weighted average by Cap. -0.28%+2.87%+17.45%+13.60%

Financials

2026 *2027 *
Net sales 704M 616M 568M 527M 1B 67.14B 1.01B 6.8B 2.65B 32.96B 2.64B 2.59B 114B 774M 678M 624M 580M 1.1B 73.83B 1.12B 7.47B 2.91B 36.24B 2.91B 2.84B 126B
Net income -183M -161M -148M -137M -261M -17.48B -264M -1.77B -689M -8.58B -688M -673M -29.76B -136M -119M -110M -102M -193M -12.97B -196M -1.31B -511M -6.36B -510M -499M -22.07B
Net Debt -222M -194M -179M -166M -316M -21.18B -320M -2.14B -834M -10.39B -834M -815M -36.04B -
Logo NovoCure Limited
NovoCure Limited is a global oncology company with a proprietary platform technology called Tumor Treating Fields (TTFields), which are electric fields that exert physical forces to kill cancer cells via a variety of mechanisms. The Company's commercialized products are approved in certain countries for the treatment of adult patients with glioblastoma, non-small cell lung cancer, malignant pleural mesothelioma and pleural mesothelioma. Its Optune Gio is approved by the FDA under the Premarket Approval pathway for the treatment of adult patients with newly diagnosed glioblastoma together with temozolomide, a chemotherapy drug, and for adult patients with GBM following confirmed recurrence after chemotherapy as monotherapy treatment. Its Optune Lua is approved by the FDA under the PMA pathway for the treatment of adult patients with metastatic non-small cell lung cancer concurrent with PD-1/PD-L1 inhibitors or docetaxel following progression on or after a platinum-based regimen.
Employees
1,605
Date Price Change Volume
07/07/26 $17.03 -1.70% 152,956
06/07/26 $17.32 +0.70% 1,711,142
02/07/26 $17.20 +9.00% 1,953,473
01/07/26 $15.78 +4.16% 1,351,505
30/06/26 $15.15 -2.13% 1,412,328
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
A
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
17.32USD
Average target price
26.00USD
Spread / Average Target
+50.12%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. NVCR Stock